Lykke Midtbøll Ørnbjerg

Author

Also Known As

L M Ornbjerg, L M Ørnbjerg, L Midtbøll Ørnbjerg, L Ørnbjerg, L. Midtbøll Ørnbjerg, L. Ørnbjerg, L.M. Ørnbjerg, Lykke M. Ørnbjerg, Lykke M Ørnbjerg, Lykke M. Ørnbjerg

151

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Glostrup Hospital University of Copenhagen Rigshospitalet Aarhus University Hospital Diakonhjemmet Hospital

About

Lykke Midtbøll Ørnbjerg is an author at Glostrup Hospital.

Lykke Midtbøll Ørnbjerg

Publications

876

Citations

H-Index

Page 1

	Year	Citations
Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis Signe Møller-Bisgaard, Kim Hørslev‐Petersen, Bo Ejbjerg, JAMA	2019	88
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration Lykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Johan Askling, Annals of the Rheumatic Diseases	2019	87
The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. Kathrine Lederballe Grøn, Lykke Midtbøll Ørnbjerg, Merete Lund Hetland, PubMed	2015	74
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration Brigitte Michelsen, Ulf Lindström, Cătălin Codreanu, RMD Open	2020	61
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration Ulf Lindström, Daniela Di Giuseppe, Bénédicte Delcoigne, Annals of the Rheumatic Diseases	2021	53
Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpA Cecilie Heegaard Brahe, Lykke Midtbøll Ørnbjerg, L. Jacobsson, Lara D. Veeken	2019	49
Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA) Kim Hørslev‐Petersen, Merete Lund Hetland, Lykke Midtbøll Ørnbjerg, Annals of the Rheumatic Diseases	2015	46
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial Mikkel Østergaard, Ronald van Vollenhoven, Anna Rudin, Annals of the Rheumatic Diseases	2023	44
Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries Brigitte Michelsen, Stylianos Georgiadis, Daniela Di Giuseppe, Arthritis Care & Research	2021	43
Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors Cecilie Heegaard Brahe, Simon Krabbe, Mikkel Østergaard, Lara D. Veeken	2018	36

Page 1